← Eichor
Condition: B Cell All Childhood Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: B Cell All Childhood

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic
Phase 1 · 8 location(s) · Autolus Limited · NCT06173518Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
Phase 2/Phase 3 · 27 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06764238Combined Immuno-chemotherapy for Patients With B-linear Acute Lymphoblastic Leukemia Diagnosed From 0 to 365 Days of Lif
Phase 3 · 1 location(s) · Federal Research Institute of Pediatric Hematology, Oncology · NCT05029531Clinical Trial of CMD63 Chimeric Antigen Receptor T-cell (CAR T-cell) in Children With Acute Lymphoblastic Leukemia (ALL
Phase 1 · 3 location(s) · Chulalongkorn University · NCT07078929CAR-T Cell Therapy for ALL
EARLY_Phase 1 · 1 location(s) · Dr. Zaineb Akram · NCT07695012A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants
Phase N/A · 2 location(s) · Arkansas Children's Hospital Research Institute · NCT07422337Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
Phase 2/Phase 3 · 27 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06882057Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia
Phase 1/Phase 2 · 11 location(s) · University Hospital Tuebingen · NCT05366218CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transp
Phase 1 · 1 location(s) · St. Jude Children's Research Hospital · NCT07257419Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
Phase 2 · 20 location(s) · Etan Orgel · NCT05082519A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With Firs
Phase 2 · 68 location(s) · Pfizer · NCT05748171CD-19 CAR-T Cell for Pediatric ALL or Lymphoma
NA · 1 location(s) · Hong Kong Children's Hospital · NCT06866873Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT
Phase 2 · 1 location(s) · Medical College of Wisconsin · NCT04746209Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
NA · 7 location(s) · Miltenyi Biomedicine GmbH · NCT06508775A Phase I Dose Finding Study of MB-CART2219.1
Phase 1 · 2 location(s) · University Hospital Tuebingen · NCT07108868ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia.
Phase 1 · 1 location(s) · National University Hospital, Singapore · NCT05038696Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cel
NA · 1 location(s) · Peking University People's Hospital · NCT06581081Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Ly
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT03136146A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
Phase 2 · 10 location(s) · Chongqing Precision Biotech Co., Ltd · NCT05334823Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Mali
Phase 1 · 2 location(s) · Sumithira Vasu · NCT05418088Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
Phase 3 · 24 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07152041Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
Phase 1/Phase 2 · 2 location(s) · University Hospital Heidelberg · NCT03676504
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.